BLAINJECTIONINJECTABLEPriority Review
Approved
Apr 2025
Lifecycle
Launch
Competitive Pressure
30/100
Clinical Trials
19
Mechanism of Action
Nipocalimab-aahu is a human IgG1 monoclonal antibody that binds to neonatal Fc receptor (FcRn), resulting in the reduction of circulating IgG levels.
Clinical Trials (5)
A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
Started Mar 2026
600 enrolled
Lupus Erythematosus, Systemic
A Study of Nipocalimab in Adult Participants With Active Lupus Nephritis
Started Jan 2026
0Lupus Nephritis
Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis
Started Jan 2026
115 enrolled
Myasthenia Gravis
A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
Started Feb 2025
50 enrolled
Thrombocytopenia, Neonatal Alloimmune
Nipocalimab in Moderate to Severe Sjogren's Disease
Started Dec 2024
655 enrolled
Sjogrens Syndrome